World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
59548
World Ranking
5450
National Ranking
2935

David P. Carbone publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David P. Carbone sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 624 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David P. Carbone D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David P. Carbone sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David P. Carbone is affiliated with The Ohio State University in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Oncology and Pulmonary and Respiratory Medicine.

The scientist has contributed extensively to the study of cancer, with particular emphasis on lung cancer and cancer immunotherapy. Their work covers several subfields, including Molecular Biology, Cancer Research, and Immunology.

Key topics in David P. Carbone's research include:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • RNA modifications and cancer
  • Immunotherapy and Immune Responses

Frequent co-authors in their publications include:

  • Carolyn J. Presley
  • Dwight H. Owen
  • Peter G. Shields
  • Kai He
  • Gregory A. Otterson

The scientist's publications appear regularly in high-profile journals. Most frequent venues include:

  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Annals of Oncology

Some recent publications with their titles, years of publication, and associated venues are:

  • "First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial" (2021), The Lancet Oncology
  • "Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches" (2021), Annals of Oncology
  • "Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial" (2022), Nature Medicine
  • "Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results" (2022), Nature Medicine
  • "First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update" (2021), ESMO Open

Best Publications

  • Comprehensive genomic characterization of squamous cell lung cancers

    Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet

  • Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.

    Dmitry I. Gabrilovich;Dmitry I. Gabrilovich;Hailei L. Chen;Khaled R. Girgis;H. Thomas Cunningham

  • First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.

    Bond Almand;Joseph I. Clark;Ekaterina Nikitina;James van Beynen

  • Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo

    Dmitry Gabrilovich;Tadao Ishida;Tsunehiro Oyama;Sophia Ran

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

    Li Yang;Laura M. DeBusk;Koari Fukuda;Barbara Fingleton

  • Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

    Li Yang;Jianhua Huang;Xiubao Ren;Agnieszka E. Gorska

  • First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

    Luis Paz-Ares;Tudor-Eliade Ciuleanu;Manuel Cobo;Michael Schenker

  • Clinical Significance of Defective Dendritic Cell Differentiation in Cancer

    Bond Almand;John R. Resser;Brian Lindman;Sorena Nadaf

  • NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway

    Masaki Terabe;So Matsui;Nancy Noben-Trauth;Hangjiong Chen

  • Non-small-cell lung cancer

    Cesare Gridelli;Antonio Rossi;David P Carbone;Juliana Guarize

  • Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo: Presented in part at the Keystone Symposium “Cellular and Molecular Biology of Dendritic Cells,” Santa Fe, NM, March 3-9, 1998, and at the annual meeting of the American Association for Cancer Research, March 28-April 1, 1998.

    Dmitry Gabrilovich;Dmitry Gabrilovich;Tadao Ishida;Tadao Ishida;Tsunehiro Oyama;Tsunehiro Oyama;Sophia Ran;Sophia Ran

  • Proteomic patterns of tumour subsets in non-small-cell lung cancer.

    Kiyoshi Yanagisawa;Yu Shyr;Baogang J Xu;Pierre P Massion

  • Delivering affordable cancer care in high-income countries

    Richard Sullivan;Jeffrey Peppercorn;Karol Sikora;John Zalcberg

  • Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

    Roy S. Herbst;David H. Johnson;Eric Mininberg;David P. Carbone

  • Erratum: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (Nature Medicine 2, 1096-1103 (1996))

    D. I. Gabrilovich;H. L. Chen;K. R. Girgis;H. T. Cunningham

  • Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells.

    Tsunehiro Oyama;Sophia Ran;Tadao Ishida;Sorena Nadaf

  • First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer

    David P. Carbone

Frequent Co-Authors

Pierre P. Massion
Pierre P. Massion Vanderbilt University Medical Center
Yu Shyr
Yu Shyr Vanderbilt University Medical Center
Gregory A. Otterson
Gregory A. Otterson The Ohio State University
Peter G. Shields
Peter G. Shields The Ohio State University
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
Hiroyuki Yamamoto
Hiroyuki Yamamoto St. Marianna University School of Medicine
Dmitry I. Gabrilovich
Dmitry I. Gabrilovich AstraZeneca (United Kingdom)
Kohzoh Imai
Kohzoh Imai University of Tokyo
John D. Minna
John D. Minna The University of Texas Southwestern Medical Center
Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine, there are several flexible online degree options and alternative pathways that can help you get started or further your education, even if you are not ready to attend medical school in the USA.

Nursing degrees are popular and accessible choices. For current registered nurses hoping to advance their qualifications affordably, explore the rn to bsn cheapest programs available online. These programs let you earn a Bachelor of Science in Nursing (BSN) while maintaining your work schedule.

If you do not already have a nursing background, there are online bsn programs for non nurses that support career changers. Additionally, you can jumpstart your career in advanced practice nursing through direct entry msn programs for non nurses online, designed for students with bachelor’s degrees in other fields.

Another high-demand healthcare profession is medical billing and coding. Online programs from the best online medical billing and coding schools offer flexibility and financial aid, making them attractive for those seeking quick entry into the industry.

Best Scientists Citing David P. Carbone

Trending Scientists

Recently Published Articles